FibroBiologics, a UK-based biotechnology company, has dosed the first patients in a clinical trial for a novel treatment of diabetic foot ulcers. This complication affects thousands of people with diabetes in the UK each year, often leading to amputation and significant morbidity.
According to the NHS, diabetic foot ulcers are a major cause of hospitalisation and amputation among people with diabetes. In 2020/21, there were 14,400 hospital admissions for diabetic foot problems in England, resulting in 1,400 amputations.
The trial, which is being conducted at multiple sites across the UK, will assess the efficacy and safety of the experimental therapy in reducing the incidence and severity of diabetic foot ulcers. The company has stated that the treatment has shown promising results in preclinical studies, but further research is needed to confirm its effectiveness in humans.
Diabetes UK estimates that there are over 4 million people living with diabetes in the UK, and the number is expected to rise to 6.5 million by 2030. The charity has highlighted the need for innovative treatments to manage the condition and prevent complications.
While the trial is ongoing, patients with diabetic foot ulcers should continue to follow their treatment plan and seek medical attention if they experience any symptoms or changes in their condition. The NHS has guidelines for the management of diabetic foot ulcers, which include regular foot checks, wound care, and antibiotics to prevent infection.